• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hepatitis B - Pipeline Review, H2 2012 Product Image

Hepatitis B - Pipeline Review, H2 2012

  • Published: November 2012
  • 269 pages
  • Global Markets Direct

Hepatitis B – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Hepatitis B - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis B, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis B. Hepatitis B - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hepatitis B.
- A review of the Hepatitis B products under development by companies and universities/research institutes based on information derived from READ MORE >

2
List of Tables 6
List of Figures 8
Introduction 10
REPORT COVERAGE 10
Hepatitis B Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Hepatitis B 12
Hepatitis B Therapeutics under Development by Companies 14
Hepatitis B Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 22
Comparative Analysis 22
Mid Clinical Stage Products 23
Comparative Analysis 23
Early Clinical Stage Products 24
Comparative Analysis 24
Discovery and Pre-Clinical Stage Products 25
Comparative Analysis 25
Hepatitis B Therapeutics – Products under Development by Companies 26
Hepatitis B Therapeutics – Products under Investigation by Universities/Institutes 32
Companies Involved in Hepatitis B Therapeutics Development 34
Bristol-Myers Squibb Company 34
F. Hoffmann-La Roche Ltd. 35
GlaxoSmithKline plc 36
Gilead Sciences, Inc. 37
Merck & Co., Inc. 38
Celltrion, Inc. 39
Achillion Pharmaceuticals, Inc. 40
Aduro BioTech 41
CEL-SCI Corporation 42
Zosano Pharma, Inc. 43
Hemispherx Biopharma, Inc. 44
Agenix Limited 45
Arrowhead Research Corporation 46
Ligand Pharmaceuticals Incorporated 47
Medivir AB 48
Benitec Ltd. 49
BioDiem Ltd 50
CytoGenix, Inc. 51
Dynavax Technologies Corporation 52
Transgene SA 53
Lipoxen PLC 54
Hepatitis B – Therapeutics Assessment 88
Assessment by Monotherapy Products 88
Assessment by Combination Products 89
Assessment by Route of Administration 90
Assessment by Molecule Type 92
Drug Profiles 95
elvucitabine - Drug Profile 95
tenofovir - Drug Profile 97
tenofovir - Drug Profile 98
Truvada - Drug Profile 99
tenofovir disoproxil fumarate - Drug Profile 101
pradefovir mesylate - Drug Profile 102
pradefovir mesylate - Drug Profile 103
lagociclovir valactate - Drug Profile 104
Vector Semliky IL12 - Drug Profile 106
Heplisav - Drug Profile 107
DNA Vaccine For Viral Infection - Drug Profile 109
DV-601 - Drug Profile 111
interferon alpha-2b - Drug Profile 112
REP-9AC - Drug Profile 114
clevudine - Drug Profile 116
HepaXen - Drug Profile 118
Vaccine For Hepatitis B - Drug Profile 119
Hepatitis B Vaccine - Drug Profile 120
TheraVax Based Hepatitis B Vaccine - Drug Profile 121
LB-80380 - Drug Profile 122
Hepatitis B Vaccine - Drug Profile 123
GSK223192A + HBsAg - Drug Profile 124
tenofovir - Drug Profile 125
Tenofovir Disoproxil Fumarate + Emtricitabine - Drug Profile 127
Lamivudine + Adefovir Dipivoxil - Drug Profile 129
HB-110 + Adefovir - Drug Profile 131
Emtricitabine + Tenofovir Disoproxil Fumarate + Hepatitis B Immunoglobulin - Drug Profile 132
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile 133
simvastatin - Drug Profile 135
Therapeutic Hepatitis B vaccine - Drug Profile 136
CYT-107 + GenHevac + Tenofovir - Drug Profile 137
Simvastatin + Tenofovir - Drug Profile 139
Simvastatin + Entecavir - Drug Profile 141
CYT-107 + GenHevac + Entecavir - Drug Profile 142
Pegasys + Tenofovir - Drug Profile 144
Pegylated Interferon Alfa-2a + Adefovir - Drug Profile 145
Aluminium Free Hepatitis B Vaccine - Drug Profile 146
Nucleotide Analogues + HBIG + HB Vaccine - Drug Profile 147
Therapeutic Hepatitis B Vaccine - Drug Profile 200
Prophylactic Hepatitis B Vaccine - Drug Profile 201
RAP-164 - Drug Profile 202
Hepatitis B Vaccine - Drug Profile 203
TG-1050 - Drug Profile 204
REP 9AC' - Drug Profile 205
cyclic thymopentin - Drug Profile 206
GC-1102 - Drug Profile 207
NU-500 - Drug Profile 208
ARC-520 - Drug Profile 209
Low Dose Protein - Drug Profile 211
Hepatitis B Vaccine - Drug Profile 212
Hepabulin IV - Drug Profile 213
HB-110 + Entecavir - Drug Profile 214
Human Hepatitis B Immunoglobulin (pH4) For Intarvenous Injection - Drug Profile 215
ChronVac-B - Drug Profile 216
Plasmid DNA Vaccine For Hepatitis B - Drug Profile 217
Hepatitis B Vaccine - Drug Profile 218
FP02 Hepatitis-B Vaccine - Drug Profile 219
Myrcludex B - Drug Profile 220
Myrcludex B - Drug Profile 222
Creaferon - Drug Profile 224
FGI-104 - Drug Profile 225
WTCc adjuvant - Drug Profile 226
Hepatitis B Therapeutics – Drug Profile Updates 228
Hepatitis B Therapeutics – Discontinued Products 246
Hepatitis B Therapeutics - Dormant Products 247
Hepatitis B – Product Development Milestones 253
Featured News & Press Releases 253
Appendix 261
Methodology 261
Coverage 261
Secondary Research 261
Primary Research 261
Expert Panel Validation 261
Contact Us 262
Disclaimer 262

List of Tables
Number of Products Under Development for Hepatitis B, H2 2012 19
Products under Development for Hepatitis B – Comparative Analysis, H2 2012 20
Number of Products under Development by Companies, H2 2012 22
Number of Products under Development by Companies, H2 2012 (Contd..1) 23
Number of Products under Development by Companies, H2 2012 (Contd..2) 24
Number of Products under Development by Companies, H2 2012 (Contd..3) 25
Number of Products under Development by Companies, H2 2012 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 28
Comparative Analysis by Late Stage Development, H2 2012 29
Comparative Analysis by Mid Clinical Stage Development, H2 2012 30
Comparative Analysis by Early Clinical Stage Development, H2 2012 31
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 32
Products under Development by Companies, H2 2012 33
Products under Development by Companies, H2 2012 (Contd..1) 34
Products under Development by Companies, H2 2012 (Contd..2) 35
Products under Development by Companies, H2 2012 (Contd..3) 36
Products under Development by Companies, H2 2012 (Contd..4) 37
Products under Development by Companies, H2 2012 (Contd..5) 38
Products under Investigation by Universities/Institutes, H2 2012 39
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 40
Bristol-Myers Squibb Company, H2 2012 41
F. Hoffmann-La Roche Ltd., H2 2012 42
GlaxoSmithKline plc, H2 2012 43
Gilead Sciences, Inc., H2 2012 44
Merck & Co., Inc., H2 2012 45
Celltrion, Inc., H2 2012 46
Achillion Pharmaceuticals, Inc., H2 2012 47
Aduro BioTech, H2 2012 48
CEL-SCI Corporation, H2 2012 49
Zosano Pharma, Inc., H2 2012 50
Hemispherx Biopharma, Inc., H2 2012 51
Agenix Limited, H2 2012 52
Arrowhead Research Corporation, H2 2012 53
Ligand Pharmaceuticals Incorporated, H2 2012 54
Medivir AB, H2 2012 55
Benitec Ltd., H2 2012 56
BioDiem Ltd, H2 2012 57
CytoGenix, Inc., H2 2012 58
Dynavax Technologies Corporation, H2 2012 59
Transgene SA, H2 2012 60
Lipoxen PLC, H2 2012 61
Green Cross Corporation, H2 2012 62
MOLOGEN AG, H2 2012 63
LG Life Sciences, Ltd, H2 2012 64
Uni-Bio Science Group Ltd., H2 2012 65
Panacea Biotec Limited, H2 2012 66
Tripep AB, H2 2012 67
Digna Biotech, S.L., H2 2012 68
Immune Network Research Ltd., H2 2012 69
Functional Genetics, Inc., H2 2012 70
Colby Pharmaceutical Company, H2 2012 71
Mucosis B.V., H2 2012 72
Cytheris SA, H2 2012 73
Mondobiotech Holding AG, H2 2012 74
AiCuris GmbH & Co. KG, H2 2012 75
Romark Laboratories, L.C., H2 2012 76
Chimerix, Inc., H2 2012 77
REPLICor Inc., H2 2012 78
Immune Targeting Systems (ITS) Ltd., H2 2012 79
Wittycell S.A.S., H2 2012 80
Genexine Co., Ltd., H2 2012 81
NanoBio Corporation, H2 2012 82
Bolder Biotechnology, Inc., H2 2012 83
ImmunoVaccine Technologies Inc., H2 2012 84
Globeimmune, Inc., H2 2012 85
PepTcell Limited, H2 2012 86
Virax Holdings Limited, H2 2012 87
GenPhar, Inc., H2 2012 88
PharmaEssentia Corporation, H2 2012 89
NasVax Ltd., H2 2012 90
China Biologic Products, Inc., H2 2012 91
Vaxine Pty Ltd, H2 2012 92
VectorLogics, Inc., H2 2012 93
ImQuest Life Sciences, H2 2012 94
Assessment by Monotherapy Products, H2 2012 95
Assessment by Combination Products, H2 2012 96
Assessment by Stage and Route of Administration, H2 2012 98
Assessment by Stage and Molecule Type, H2 2012 101
Hepatitis B Therapeutics – Drug Profile Updates 235
Hepatitis B Therapeutics – Discontinued Products 253
Hepatitis B Therapeutics – Dormant Products 254
Hepatitis B Therapeutics – Dormant Products (Contd..1) 255
Hepatitis B Therapeutics – Dormant Products (Contd..2) 256
Hepatitis B Therapeutics – Dormant Products (Contd..3) 257
Hepatitis B Therapeutics – Dormant Products (Contd..4) 258
Hepatitis B Therapeutics – Dormant Products (Contd..5) 259

List of Figures
Number of Products under Development for Hepatitis B, H2 2012 19
Products under Development for Hepatitis B – Comparative Analysis, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 27
Late Stage Products, H2 2012 29
Mid Clinical Stage Products, H2 2012 30
Early Clinical Stage Products, H2 2012 31
Discovery and Pre-Clinical Stage Products, H2 2012 32
Assessment by Monotherapy Products, H2 2012 95
Assessment by Combination Products, H2 2012 96
Assessment by Route of Administration, H2 2012 97
Assessment by Stage and Route of Administration, H2 2012 98
Assessment by Molecule Type, H2 2012 99
Assessment by Stage and Molecule Type, H2 2012 100

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos